{
    "clinical_study": {
        "@rank": "45198", 
        "arm_group": [
            {
                "arm_group_label": "Phase I - Dose Escalation", 
                "arm_group_type": "Experimental", 
                "description": "For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.\nPhase I will be followed by an expansion Phase Ib."
            }, 
            {
                "arm_group_label": "Arm A: Dose Expansion", 
                "arm_group_type": "Experimental", 
                "description": "Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.\nThe treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
            }, 
            {
                "arm_group_label": "Arm B: Dose Expansion", 
                "arm_group_type": "Experimental", 
                "description": "Phase Ib Arm B:  KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.\nThe treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to find out if the drugs MEK162 and erlotinib (Tarceva)\n      given in combination are safe and have beneficial effects in patients who have NSCLC.\n\n      The U.S. Food and Drug Administration (FDA) has not approved MEK162 for use to treat NSCLC.\n      Erlotinib is an FDA approved drug for the treatment of Non-Small Cell Lung Cancer."
        }, 
        "brief_title": "A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "Non-Small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible patients will have a histologic or cytologic diagnosis of NSCLC of the\n             advanced stage (IV), with no known curative treatment options.\n\n          -  Have a biopsy proven KRAS or EGFR mutation confirmed in a Clinical Laboratory\n             Improvement Amendments (CLIA)certified lab (only required in the Phase IB expansion\n             cohort).\n\n          -  For Phase I enrollment, all patients must have received at least one previous line of\n             therapy; the sole exception is for patients who are EGFR tyrosine kinase inhibitor\n             (TKI) naive and have CLIA confirmed EGFR mutation other than include an EGFR exon 19\n             deletions or exon 21 (L858R) substitution mutations; these patients may enroll on the\n             phase I study as first line treatment.\n\n          -  For Phase IB enrollment, all patients must have received at least one previous line\n             of therapy; the sole exception is for patients who are EGFR-TKI naive and harbor a\n             CLIA confirmed EGFR mutation, they may enroll in the Phase IB portion of the study as\n             first line treatment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1\n\n          -  Patients will have received no more than 4 lines of previous chemotherapy for\n             metastatic NSCLC in the Phase I arm only.\n\n          -  Patients will have received no more than 2 lines of previous chemotherapy for\n             metastatic NSCLC in the Phase IB arm only.\n\n          -  At least one measurable site of disease (as defined by Response Evaluation Criteria\n             in Solid Tumors), or other disease specific response assessment criteria, as\n             appropriate (RECIST 1.1).\n\n          -  Have discontinued all previous systemic therapies and recovered from side effects due\n             to systemic treatment for more than 28 days prior to starting on treatment.\n\n          -  Have discontinued all previous biologic therapies and recovered from side effects due\n             to biologic treatment for more than 28 days prior to starting on treatment.\n\n          -  Have discontinued all previous external beam radiation therapy and recovered from\n             side effects due to radiation therapy for more than 28 days prior to starting on\n             treatment.\n\n          -  Erlotinib na\u00efve (required for both Phase I and IB).\n\n          -  Have archival tissue available or be willing to undergo a repeat biopsy.\n\n          -  Negative serum pregnancy test within 72 hours prior to the first study dose in all\n             women of childbearing potential (WOCBP).\n\n          -  Adequate organ function and lab parameters\n\n          -  Prior to any screening or invasive procedure, written informed consent must be\n             obtained.\n\n        Exclusion Criteria:\n\n          -  Does not have adequate cardiac function\n\n          -  Patients with documented central nervous system or leptomeningeal metastasis (brain\n             metastasis) at time of study entry. Patients with prior brain metastasis may be\n             considered if they have completed their treatment for brain metastasis, no longer\n             require corticosteroids, and are asymptomatic.\n\n          -  Any other serious uncontrolled medical disorder or active infection that would impair\n             the patient's ability to receive study treatment\n\n          -  Prior use of MEK162 or concurrent use of other approved anticancer (except erlotinib\n             per this study protocol) or investigational agents\n\n          -  Gastrointestinal disease that precludes absorption\n\n          -  History or current evidence of central serous retinopathy (CSR) or retinal vein\n             occlusion (RVO)\n\n          -  Any ophthalmopathy visible at screening that would be considered a risk factor for\n             CSR or RVO by the ophthalmologist\n\n          -  History of another malignancy within 2 years, except cured basal cell carcinoma of\n             the skin or excised carcinoma in situ of the cervix\n\n          -  Patients who have received prior anti-cancer treatment within the following time\n             frames: systemic therapies less than 28 days prior to starting on treatment;\n             radiation therapy less than 28 days prior to starting on treatment; biologic therapy\n             less than 28 days prior to starting on treatment.\n\n          -  Patients who have not recovered from side effects of prior anti-cancer treatment to\n             less than or equal to grade 1 toxicity according to Common Toxicity Criteria for\n             Adverse Effects (CTCAE) v.4 within the following time frames: Received previous\n             systemic therapy and has not recovered from side effects for more than 28 days prior\n             to starting on treatment; Received previous radiation therapy and has not recovered\n             from side effects for more than 28 days prior to starting on treatment; Received\n             previous biologic therapy and has not recovered from side effects for more than 28\n             days prior to starting on treatment\n\n          -  Have undergone major surgery < 4 weeks of initiation of study medication or who have\n             not recovered from side effects of such procedure\n\n          -  Patients with concurrent uncontrolled medical conditions that may interfere with\n             their participation in the study or potentially affect the interpretation of the\n             study data\n\n          -  Women who are pregnant or nursing\n\n          -  Women of child-bearing potential (WOCBP) and males who have not been sterilized by\n             vasectomy or other means with partners who are WOCBP, UNLESS the women are using two\n             birth control methods. The two methods can be a double barrier method or a barrier\n             method plus a hormonal method.\n\n          -  Unwilling or unable to comply with the protocol\n\n          -  Known positive serology for HIV, active Hepatitis B, and/or active Hepatitis C\n             infection\n\n          -  History of Gilbert's syndrome\n\n          -  Neuromuscular disorders that are associated with elevated creatinine kinase (CK)\n\n          -  Patients who are planning on embarking on a new strenuous exercise regimen after\n             first dose of study treatment. Muscular activities, such as strenuous exercise, that\n             can result in significant increases in plasma CK levels should be avoided while on\n             MEK162 treatment.\n\n          -  Previous treatment with any substrate of CYP2B6 enzyme < 14 days prior to initiation\n             of investigational products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859026", 
            "org_study_id": "MCC-17361", 
            "secondary_id": "CMEK162XUS04T"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase I - Dose Escalation", 
                    "Arm A: Dose Expansion", 
                    "Arm B: Dose Expansion"
                ], 
                "description": "Treatment as outlined in study arms.", 
                "intervention_name": "MEK162", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARRY-162", 
                    "ARRY-438162", 
                    "Mitogen Activated Kinase (MEK) inhibitor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Phase I - Dose Escalation", 
                    "Arm A: Dose Expansion", 
                    "Arm B: Dose Expansion"
                ], 
                "description": "Treatment as outlined in study arms.", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Tarceva", 
                    "CP-358,774", 
                    "OSI-774", 
                    "Reversible tyrosine kinase inhibitor", 
                    "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitogens", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Epidermal growth factor receptor (EGFR)", 
            "EGFR mutation", 
            "Kirsten rat sarcoma 2 viral oncogene homolog(KRAS)", 
            "KRAS mutation", 
            "Non-Small Cell Lung Cancer (NSCLC)", 
            "Advanced-stage IV"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://www.moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "milijana.ugrenovic@moffitt.org", 
                "last_name": "Milijana Ugrenovic", 
                "phone": "813-745-2010"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Scott Antonia, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alberto Chiappori, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Richard Hall, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Haura, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mary Pinder-Schenck, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tawee Tanvetyanon, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charles Williams, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Jhanelle Gray, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety of MEK162 plus erlotinib in patients with advanced NSCLC by evaluating toxicities of therapy and establish a recommended phase IB dosing of MEK162 and erlotinib. Safety population: consists of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment.", 
            "measure": "Phase I: Maximum Tolerated Dose (MTD)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859026"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the duration of time from the time of randomization to time of disease progression or death, whichever occurs first. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).", 
                "measure": "Number of Participants with Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "OS, defined as the time from study enrollment to death from any cause during the study duration.", 
                "measure": "Number of Participants with Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}